Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors

Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors

BackgroundImmune checkpoint inhibitors (ICIs) are an important treatment modality that must be considered for patients with lung adenocarcinoma (LUAD). However, ICIs are effective only in some of these patients. Therefore, identifying biomarkers that accurately predict the prognosis of patients with...

Full description

Bibliographic Details
Main Authors: Yuchun Niu, Anqi Lin, Peng Luo, Weiliang Zhu, Ting Wei, Ruixiang Tang, Linlang Guo, Jian Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-08-01
Series:Frontiers in Pharmacology
Subjects:
immune checkpoint inhibitors
prognosis
lung adenocarcinoma (LUAD)
NTRK3
mutations
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2020.01213/full

Similar Items

Similar Items